Alexza Pharmaceuticals, Inc.

Alexza Molecular Delivery Corporation

Princeton University

Memorial Sloan Kettering Cancer Center

Arbor Vita Corporation

Other

University of Pennsylvania

Njoy, Inc.

Alexza Molecula Delivery Corporation

Joshua D Rabinowitz

Alejandro C Zaffaroni

Ron L Hale

Martin J Wensley

Peter Lloyd

Daniel J Myers

Craig C Hodges

Amy Tsai Lu

Dennis Solas

Reynaldo J Quintana

Jeffrey Alan McKinney

Soonho Song

Thomas E Shenk

Gregory S Ducker

Hahn Kim

Jonathan M Ghergurovich

Daniel David Rogers

Daniel Mufson

Peter S Lu

Craig B Thompson

Johannes Schweizer

Josh Munger

Bryson Bennett

Jurre Kamphorst

Curtis Peter Tom

Emre Koyuncu

Justin Cross

Jing Fan

Mark A Scatterday

Nathan Every

Michael P Belmares

Krishnamohan Sharma

Stephen D Cross

Patrik Munzar

Roderick O'Connor

Jiangbin Ye

Sean Liu

Daniel D Rogers

Peter M Lloyd

Jeffrey A Mckinney

Stephen Cross

Amy T Lu

The present invention provides, in some embodiments, methods of promoting an immune response in a subject in need thereof, comprising administering to the subject a population of immune cells that express an enzyme that facilitates immune cell function in a nutrient-poor environment. The invention also provides, in other embodiments, compositions comprising an ex vivo population of immune cells expressing an enzyme that enhances immune cell function in a nutrient-poor environment.

Immunotherapy with metabolic enzyme expression

The disclosure provides compounds. In certain embodiments, compounds of the disclosure are capable of inhibiting a mammalian SHMT, such as human SMHT1 and/or SHMT2. Compounds of the disclosure have numerous uses.

SHMT inhibitors

The present invention an electronic inhaler for the delivery of pharmaceuticals through vaporization.

Methods and devices for controlled drug vaporization

A 10-formyl-THF pathway for producing NADPH is useful in the diagnosis and treatment of cancer and metabolic disease, in the development of new antineoplastic agents and/or regimens, in the development of new methods for measuring metabolic pathway activity, and in the development of new therapeutics for treating metabolic disease.

NADPH production by the 10-formyl-THF pathway, and its use in the diagnosis and treatment of disease

The present disclosure generally relates to compositions, and related devices and methods, useful in vaporizing devices such as electronic cigarettes. The composition may comprise nicotine, at least one solvent, and at least one ion pairing agent, and may be vaporized to form a condensation aerosol, wherein inhalation of the aerosol allows for deposition of nicotine with the respiratory system, including deep lung deposition. The vaporizing device may comprise a vaporization unit, a battery, and an integrated circuit coupled to the battery, wherein the integrated circuit is configured to control the battery for rapid initial vaporization without overheating, producing thermal degradation products, or draining battery energy. The battery may operate with pulse width modulation for at least a portion of the time the vaporizing device is being used.

Compositions, devices, and methods for nicotine aerosol delivery

Methods and compositions for treating cancer and other disorders associated with undesired cellular proliferation are provided comprising administering to a subject in need thereof an amino acid mixture, wherein the amino acid mixture comprises glycine, optionally comprising at least a 2:1 molar ratio of glycine to serine.

Dietary supplements and composition for treating cancer

The disclosure provides compounds of Formulae (I)-(IX). The disclosed compounds are capable of inhibiting a mammalian SHMT. Compounds of the disclosure have numerous uses, such as for treatment of cancer or autoimmune disorders.

Methods and compositions for treating Ras-related cancers are provided that involve targeting lipid scavenging. Methods and compositions for identifying and/or characterizing more or less responsive cancers are also provided.

Lipid scavenging in Ras cancers

The present invention relates to a method for the treatment of cancer or an autoimmune disorder, comprising the administration of a serine hydroxymethyltransferase (SHMT) inhibitor, and in particular the administration of pyrazolopyran compounds of Formula (VI) as presently described, wherein the compounds are capable of inhibiting a mammalian SHMT, such as human SHMT1 and/or SHMT2. The treatment method further comprises the optional administration of an additional agent as a rescue therapy to reduce toxicity, wherein said agent may be chosen from formate, a formate salt, folinic acid, formate ester, or leucovorin.

The disclosure provides compounds of Formulae (I)-(IX). The disclosed compounds are capable of inhibiting a mammalian SHMT. Compounds of the disclosure have numerous uses, such as for treatment of cancer or autoimmue disorders.

The present invention provides novel condensation aerosols for the treatment of disease and/or intermittent or acute conditions. These condensation aerosols have little or no pyrolysis degradation products and are characterized by having an MMAD of between 1-3 microns. These aerosols are made by rapidly heating a substrate coated with a thin film of drug having a thickness of between 0.05 and 20 &#x3bc;m, while passing a gas over the film, to form particles of a desirable particle size for inhalation. Kits comprising a drug and a device for producing a condensation aerosol are also provided. The device contained in the kit typically, has an element for heating the drug which is coated as a film on the substrate and contains a therapeutically effective dose of a drug when the drug is administered in aerosol form, and an element allowing the vapor to cool to form an aerosol. Also disclosed, are methods for using these aerosols and kits.

Drug condensation aerosols and kits

Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in 'suicide' of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated.

Treatment of viral infections by modulation of host cell metabolic pathways

Growing community of inventors

Mountain View, CA, United States of America

Joshua D Rabinowitz